Skip to content

Ponoi II Management, LLC

Follow

13F filer, CIK 1746488, San Francisco, CA

Ponoi II Management, LLC reported $38,258,000 across 4 holdings for the quarter ended 2022-09-30, in a 13F-HR filed 2022-11-14.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-22-012307

Period
2022-09-30
Reported value
$38.3M
Holdings
4
Top 10 weight
100%
New
0
Sold out
0

Holdings, Q3 2022

Share positions as resolved from 13F-HR 0000950123-22-012307, largest first. % of portfolio is the value over $38,258,000, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
NGM BIOPHARMACEUTICALS INCNGM BIOPHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q4: 1,298,908 shares; 2021Q1: 1,298,908 shares; 2021Q2: 1,298,908 shares; 2021Q3: 1,298,908 shares; 2021Q4: 1,298,908 shares; 2022Q1: 1,298,908 shares; 2022Q2: 1,298,908 shares; 2022Q3: 1,298,908 shares 1,298,908$17M44.41%0
RVMDREVOLUTION MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q4: 685,011 shares; 2021Q1: 685,011 shares; 2021Q2: 685,011 shares; 2021Q3: 685,011 shares; 2021Q4: 685,011 shares; 2022Q1: 685,011 shares; 2022Q2: 685,011 shares; 2022Q3: 685,011 shares 685,011$13.5M35.31%0Timeline
NRIXNURIX THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q4: 686,274 shares; 2021Q1: 686,274 shares; 2021Q2: 686,274 shares; 2021Q3: 561,574 shares; 2021Q4: 327,123 shares; 2022Q1: 327,123 shares; 2022Q2: 327,123 shares; 2022Q3: 327,123 shares 327,123$4.26M11.14%0Timeline
RAPT THERAPEUTICS INCRAPT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q4: 145,401 shares; 2021Q1: 145,401 shares; 2021Q2: 145,401 shares; 2021Q3: 145,401 shares; 2021Q4: 145,401 shares; 2022Q1: 145,401 shares; 2022Q2: 145,401 shares; 2022Q3: 145,401 shares 145,401$3.5M9.14%0

How Q3 2022 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000950123-22-012307 base2022-11-14acceptance time not in the bulk data set